Meditation and Biofeedback to Improve Anxiety, Depression and Quality of Life in Inpatients After Stroke
Study Details
Study Description
Brief Summary
The goal of this clinical trial is to investigate the impact of a technology-based meditation program in the inpatient stroke population. It will explore how this approach can support patient-centred, holistic, compassionate care by reducing symptoms of depression and anxiety and improving quality of life. Patients will be recruited from the inpatient stroke rehabilitation unit and will have sustained a stroke in the past 2 months. The main question[s] it aims to answer are:
-
Is using a technology-based meditation program in the prevention and/or improvement of post stroke depression and anxiety effective for inpatient stroke survivors?
-
Does using a technology-based meditation program support patient-centered, holistic and compassionate care and result in improved measures of quality of life?
Those in the treatment arm will be asked to complete the following:
-
complete 3 scales on admission and discharge
-
participate in meditation therapy at least three times per week for 30 minute sessions Participate in education and demonstration of the meditation app and use of the iom2 device
-
use the iom2 (technology supported meditation and biofeedback) device to monitor heart rate variability and resonance scores
-
participate in an informal discussion re: experience with software and biofeedback
In this RCT, those allocated to the control group (standard care) will undergo their usual inpatient rehabilitation but will be asked to complete the outcome measures on admission and prior to hospital discharge.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Inpatients at St. John's Rehab Hospital (A3 Unit) who experienced a stroke within the past two months will be approached to participate in the study. A member of the circle of care will identify the potential participant to see if they are interested in learning more about the study. If they are interested, a member of the research team who is NOT part of their care (e.g., the principal investigator- Mrs. Amanda Ratner) will undertake the informed consent process. For those individuals identified as experiencing aphasia, a pictographic version of the consent form will be provided. Participants will be given at least 48 hours to review the information before being asked to consent. Once consent is obtained, all participants will be screened with the PHQ-9 (Patient Health Questionnaire) (if they do not have significant levels of aphasia) or the SADQ-10 (Stroke Aphasic Depression Questionnaire (if they have significant levels of aphasia) will be used to identify the risk of post stroke depression. The HAM-A (Hamilton Anxiety Rating Scale) will be used to screen for anxiety for all participants. For participants with aphasia, the The Behavioural Outcomes of Anxiety Scale (BOA) will be used. If patients score as "at risk" on any of the screening tools, they will be randomly assigned to either the no treatment control or the treatment group. Participants who have no indications of being at risk for depression or anxiety will be thanked for their time, and no further study interventions will be undertaken with them.
For those participants who are 'at risk' for depression or anxiety, the following participant characteristics will be collected: type of stroke, date of stroke, age, visual neglect, presence/type of aphasia, The NIH Stroke Scale (NIHSS) score for stroke severity (Lyden et al., 1999), and the Montreal Cognitive Assessment (MOCA) score (Nassredine et al., 2005). These measures are collected as part of routine standard care for all patients and will be obtained from the participants' charts.
A simple randomization method will be used to allocate participants to either the treatment arm or control arm of the study. This randomization will be done prior to start of the study whereby an online randomizer will be used to determine group allocation. A person not involved in the data collection or analysis of the findings will be responsible for generating the randomization sequence (to start with treatment or to start with standard care), and will be blinded to which participants are allocated to which group. Since it is impossible to blind the study participants, we will request they not discuss their group allocation with the coordinator who is collecting the outcome measure data, but it is possible they may inadvertently reveal this to the coordinator. Consequently, this will serve to inform the feasibility of blinding study staff for a future trial. If the staff becomes unblinded, we will make a note and the coordinator will continue to collect data. However, the person analyzing the survey data will be blinded to group allocation (group 1 versus group 2) only.
For those allocated to the control group (standard care), they will undergo their inpatient rehabilitation but will be asked to complete the outcome measures again prior to hospital discharge.
For those allocated to the treatment arm (iom2 - technology supported meditation), participants will receive technology-based meditation therapy at least three times per week for 30 minute sessions. They will participate in sessions throughout the length of their inpatient stay via the iom2 device and the interactive meditation software. At their first treatment visit, the participants will be provided education about the study and will be given a brief and simple explanation and demonstration of the meditation App (Journeys). As well, they will be given an overview of the study technology with the patient in a simple language Guided demonstration of the "Journeys" app and the iom2 device. All participants' will be given the opportunity to ask questions and receive additional support where required. It is expected that participants will be able to engage in these sessions independently but study personnel will be available at the beginning and end of each session to ensure accurate use of the technology, data collection and response to any questions. During and following each session, participants will be shown their average HRV (Heart Rate Variability) score, average HRV, and time spent on the session. Patients will be able to review sessions and keep track of their progress. Participants in the intervention arm will be asked to complete the outcome measures prior to their hospital discharge. As well, an informal discussion about the patient's experience using technology based meditation will be transcribed. All participants will be thanked for their time on the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Technology Supported Meditation Patient's randomized to the treatment arm will receive technology-based meditation therapy at least three times per week for 30 minute sessions. They will participate in sessions throughout the length of their inpatient stay via the iom2 device and the interactive meditation software. Signals from the iom2 are then sent to an App on a phone, tablet or personal computer that generates biofeedback information and allows patients to adjust their breathing based on the feedback. The interactive Meditation programs teach specific breathing, mindfulness and relaxation techniques to increase a person's heart rate variability (HRV). Doing so provides the participant with instantaneous awareness of their nervous system state, which helps them to learn to directly influence their HRV. |
Behavioral: Technology Supported Meditation and Biofeedback
Patient's in the treatment arm will participate in technology based meditation using the iom2 and Journeys app at least 3 times/ week. This will involve placing a probe on their ear attached to the iom2 and following the guidance provided by the Journeys App.
During and following each session, participants will be shown their average heart rate variability (HRV) score, average HRV, and time spent on the session. Patients will be able to review sessions and keep track of their progress. Participants in the intervention arm will be asked to complete the outcome measures prior to their hospital discharge. As well, an informal discussion about the patient's experience using technology based meditation will be transcribed.
Other Names:
|
| Active Comparator: Standard Treatment Patients at St. John's Rehab undergoing rehabilitation are supported by an interprofessional team - including physiatrists, nurses, occupational therapists, speech language pathologists, physical therapists, social workers and psychiatrists. During their inpatient stay, patients receive a wide range of rehabilitation services aimed at addressing their physical, emotional and cognitive care needs. Length of stay for inpatient services ranges between 2 to 12 weeks. |
Other: Standard Treatment
Patients at St. John's Rehab undergoing rehabilitation are supported by an interprofessional team - including physiatrists, nurses, occupational therapists, speech language pathologists, physical therapists, social workers and psychiatrists. During their inpatient stay, patients receive a wide range of rehabilitation services aimed at addressing their physical, emotional and cognitive care needs. Length of stay for inpatient services ranges between 2 to 12 weeks.
|
Outcome Measures
Primary Outcome Measures
- The Patient Health Questionnaire (PHQ-9) [1) Pre-intervention: up to 2 weeks before the intervention start date. 2) Post-intervention: up to 2 weeks after the intervention end date.]
The PHQ-9 can be used as a screening tool for depression, with summed score ranging from 0 (no depressive symptoms) to 27 (all symptoms occurring daily). An item was also added to the end of the diagnostic portion of the PHQ-9 asking patients who checked off any problems on the questionnaire: "How difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?". In primary care patients, a PHQ-2 score ≥3 has 83% sensitivity and 92% specificity for identifying patients with major depression. There is evidence that the PHQ-9 performs well as a brief screener for post-stroke depression with operating characteristics similar or superior to other depression measures. Moreover, PHQ-9 scores discriminate equally well between those with and without post-stroke depression regardless of age, gender, or ethnicity.
- The Stroke Aphasic Depression Questionnaire-10 (SADQ-10) [1) Pre-intervention: up to 2 weeks before the intervention start date. 2) Post-intervention: up to 2 weeks after the intervention end date.]
The SADQ was developed to detect depressed mood in aphasic patients. It is a 21-item questionnaire developed based on observable behaviours thought to be associated with depressed mood and is completed by the client's caregiver on behalf of the client. A shortened version of the SADQ has been developed (SADQ-10), which is comprised of 10 questions that best differentiate those with high scores on depression questionnaires from those with low scores. The SADQ-10 is scored by assigning corresponding numeric values to observer selections ("Never" = 0, "Always" = 3), with a higher score indicating more depressive symptoms. In a subsequent study among patients without aphasia, a threshold of 14/30 was found to indicate clinically significant symptoms of depression (70% sensitivity and 77% specificity).
- Hamilton Anxiety Rating Scale (HAM-A) [1) Pre-intervention: up to 2 weeks before the intervention start date. 2) Post-intervention: up to 2 weeks after the intervention end date.]
The HAM-A consists of 14 symptom-defined elements, and caters for both psychological and somatic symptoms, comprising anxious mood; tension (including startle response, fatigability, restlessness); fears (including of the dark/strangers/crowds); insomnia; 'intellectual' (poor memory/difficulty concentrating); depressed mood (including anhedonia); somatic symptoms (including aches and pains, stiffness, bruxism); sensory (including tinnitus, blurred vision); cardiovascular (including tachycardia and palpitations); respiratory (chest tightness, choking); gastrointestinal (including irritable bowel syndrome-type symptoms); genitourinary (including urinary frequency, loss of libido); autonomic (including dry mouth, tension headache) and observed behaviour at interview (restless, fidgety, etc.). Each item is scored on a basic numeric scoring of 0 (not present) to 4 (severe): >17/56 is taken to indicate mild anxiety; 25-30 is considered moderate-severe.
- Stroke Specific Quality of Life Scale (SS-QOL) [1) Pre-intervention: up to 2 weeks before the intervention start date. 2) Post-intervention: up to 2 weeks after the intervention end date.]
The SS-QOL consists of 49 items covering 12 domains: Mobility, Energy, Upper Extremity Function, Work and Productivity, Mood, Self-Care, Social Roles, Family Roles, Vision, Language, Thinking and Personality. Each domain is measured by three to six items using a 5-point (1-5) Likert scale (higher scores indicate better function). An average non-weighted raw score for each domain can be generated. The overall SS-QOL summary score is most often used as the primary outcome, although the separate domain scores are helpful for identifying specific areas that are affected by stroke or that improve the most or least over time.
- The Behavioural Outcomes of Anxiety scale (BOA) [1) Pre-intervention: up to 2 weeks before the intervention start date. 2) Post-intervention: up to 2 weeks after the intervention end date.]
The BOA is an observational tool. It is designed to measure signs of anxiety that are readily observable by carers. It offers 10 descriptors of anxiety based on diagnostic criteria. It requires individuals select the box which comes closest to how s/he has been feeling in the past week. The scale ranges from "often" (3) to "Never" (0).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult (18 years and older)
-
Inpatient rehabilitation patients at St. John's Rehab
-
Experienced a stroke within the past two months prior to study enrollment
-
Identified as being at risk for depression and/or anxiety based on their scores on study screening tools
-
Able to comply with study requirements
Exclusion Criteria:
-
Younger than 18 years old
-
Significant comorbidity including psychiatric or neurological disorder (not including premorbid depression or anxiety)
-
Inability to complete any of the screening tools
-
Starting a new antidepressant or a change in antidepressant medication within the past 6 months
-
Inability to provide informed consent
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sunnybrook Health Sciences Centre
- Sunnybrook Research Institute
Investigators
- Principal Investigator: Amanda Ratner, M.Sc., M.H.Sc. SLP(C) Reg., Sunnybrook Health Sciences Centre
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 5628